Industries > Pharma > Global Acute Myeloid Leukaemia Market Forecast 2018-2028

Back to Pharma Reports

Global Acute Myeloid Leukaemia Market Forecast 2018-2028

Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib

PUBLISHED: 21 September 2018

PAGES: 135

PRODUCT CODE: PHA0332

SUBMARKET: Therapeutic Drugs

SKU: PHA0332 Categories: Pharma, Therapeutic Drugs Tags: PHA0332, PHA0351, PHA0417

The global acute myeloid leukaemia market reached $1bn in 2017 and is estimated to reach $2.8bn by 2022. In 2017, the chemotherapy segment held 69% of the global acute myeloid leukaemia market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 135-page report you will receive 92 charts– all unavailable elsewhere.

The 135-page report provides clear detailed insight into the acute myeloid leukaemia market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Acute Myeloid Leukaemia Market from 2018-2028

• Forecast of the Global Acute Myeloid Leukaemia market by Treatment Type and Product Type:
• Chemotherapy: Cytarabine, Daunorubicin, Others
• Targeted Therapy: Midostaurin, Enasidenib, Others

• This report provides individual revenue forecasts to 2028 for these regional and national markets:
• North America: US, Canada, and Mexico
• Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe
• Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific
• LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEA

• Our study discusses the selected leading companies that are the major players in the acute myeloid leukaemia market:
• Bristol-Myers Squibb Company
• Celgene
• Clavis Pharma ASA
• Daiichi Sankyo
• Eisai
• GSK
• Novartis
• Roche
• Sunesis Pharmaceuticals
• Teva

• This report discusses factors that drive and restrain the acute myeloid leukaemia market. This report also discusses the opportunities that can be tapped in this market.

• This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.

Visiongain’s study is intended for anyone requiring commercial analyses for the acute myeloid leukaemia market. You find data, trends and predictions.

Buy our report today Acute Myeloid Leukaemia Market Analysis : Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1. Report Overview

1.1 Global Acute Myeloid Leukaemia Market Overview

1.2 Market Definition & Scope

1.3 Overview of Findings

1.4 Structure of the Report1.5 Key Questions Answered by This Analytical Report

1.6 How This Report Delivers

1.7 Who is This Report For?

1.8 Methodology

1.8.1 Primary Research

1.8.2 Secondary Research

1.8.3 Market Evaluation & Forecasting Methodology

1.9 Frequently Asked Questions (FAQ)

1.10 Associated Visiongain Reports

1.11 About Visiongain

2. Introduction to Acute Myeloid Leukaemia

2.1 Market definition and scope

2.2 Myeloid Leukaemia: An Overview

2.2.1 Phases of treatment

2.2.2 Medication Overview

2.3 The Need of Acute Myeloid Therapeutics

3. Acute Myeloid Leukaemia Market: World Market 2018-2028

3.1 The World Acute Myeloid Leukaemia Market Overview and Segmentation, 2017

3.2 World Acute Myeloid Leukaemia Market: Sales Forecast 2017-2028

3.3 How Will Segments Market Shares Change to 2028?

4. Global Acute Myeloid Leukaemia Market by Treatment Type 2018-2028

4.1 Market Size and Forecast 2017-2028

4.2 Chemotherapy

4.2.1 Chemotherapy Market Size and Forecast 2017-2028

4.2.2 Cytarabine Market Size 2017-2028

4.2.3 Daunorubicin Market Size 2017-2028

4.2.4 Other Chemotherapy Products Market Size 2017-2028

4.3 Targeted Therapy

4.3.1 Targeted Therapy Market Size and Forecast 2017-2028

4.3.2 Midostaurin Market Size and Forecasts 2017-2028

4.3.3 Enasidenib Market Size and Forecasts 2017-2028

4.3.4 Other Targeted Therapy Products Market Forecasts 2017-2028

5. Global Acute Myeloid Leukaemia Market by Region 2018-2028

5.1 Global Acute Myeloid Leukaemia Market by Region: Revenue Forecast, 2018-2028

5.2 North America AML Market Forecast 2017-2028

5.2.1 North America Acute Myeloid Leukaemia Market by Country: Revenue Forecast, 2018-2028

5.2.1.1 US Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.2.1.2 Canada Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.2.1.3 Mexico Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.3 Europe Acute Myeloid Leukaemia Market Forecast 2017-2028

5.3.1 Europe Acute Myeloid Leukaemia Market by Country: Revenue Forecast, 2018-2028

5.3.1.1 Germany Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.3.1.2 France Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.3.1.3 United Kingdom Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.3.1.4 Italy Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.3.1.5 Spain Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.3.1.6 Russia Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.3.1.7 Rest of Europe Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.4 Asia-Pacific Acute Myeloid Market Forecasts 2018-2028

5.4.1 Asia-Pacific Acute Myeloid Leukaemia Market by Country: Revenue Forecast, 2018-2028

5.4.1.1 Japan Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.4.1.2 China Acute Myeloid Leukaemia Market, Revenue Forecast, 2018-2028

5.4.1.3 Australia Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.4.1.4 South Korea Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.4.1.5 India Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.4.2 Rest of Asia-Pacific Acute myeloid leukaemia Market, Revenue Forecast, 2018-2028

5.5 LAMEA Acute Myeloid Market Forecasts 2018-2028

5.5.1 LAMEA Acute Myeloid Leukaemia Market by Country: Revenue Forecast, 2018-2028

5.5.1.1 Brazil Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.5.1.2 Saudi Arabia Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.5.1.3 Republic of South Africa Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

5.5.1.4 Rest of LAMEA Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028

6. Leading Companies in Acute Myeloid Leukaemia Market

6.1 Daiichi Sankyo

6.1.1 Company Overview

6.1.2 Financial Highlights

6.1.3 Recent Strategic Developments

6.2 Celgene Corporation

6.2.1 Company Overview

6.2.2 Operating Segments

6.2.3 Financial Highlights

6.2.4 Recent Strategic Developments

6.3 TEVA Pharmaceutical Industries Limited

6.3.1 Company Overview

6.3.2 Operating Segments

6.3.3 Financial Highlights

6.3.4 Recent Strategic Developments

6.4 Eisai Co., Ltd.

6.4.1 Company Overview

6.4.2 Operating Segments

6.4.3 Financial Highlights

6.5 Novartis AG

6.5.1 Company Overview

6.5.2 Operating Segments

6.5.3 Financial Highlights

6.5.4 Recent Strategic Developments

6.6 GlaxoSmithKline plc

6.6.1 Company Overview

6.6.2 Operating Segments

6.6.3 Financial Highlights

6.7 Sunesis Pharmaceuticals, Inc.

6.7.1 Company Overview

6.7.2 Operating Segments

6.7.3 Financial Highlights

6.8 Clavis Pharma ASA

6.8.1 Company Overview

6.9 F. Hoffmann-La Roche Ltd.

6.9.1 Company Overview

6.9.2 Operating Segments

6.9.3 Financial Highlights

6.9.4 Recent Strategic Developments

6.10 Bristol-Myers Squibb Company

6.10.1 Company Overview

6.10.2 Operating Segments

6.10.3 Financial Highlights

7. Acute Myeloid Leukaemia Market: Qualitative Analysis

7.1 Market Dynamics

7.1.1 Drivers

7.1.1.1 Rise in Cases of Chronic Diseases

7.1.1.2 Research for Innovative Therapeutics

7.1.1.3 Growth in Aging Population Base Worldwide

7.1.2 Restraints

7.1.2.1 Adverse Effects of the Treatment

7.1.3 Opportunities

7.1.3.1 Unmet oncological therapeutics demand.

7.1.3.2 Untapped opportunities in the developing nations

8. Pipeline and clinical trials analysis

8.1 Pipeline analysis

8.1.1 Vosaroxin (Sunesis Pharmaceuticals)

8.1.2 CPX-351 (Celator Pharmaceuticals, Inc.)

8.1.3 Sapacitabine (Cyclacel)

8.1.4 SGI-110 (Astex)

8.2 Small-Molecule Targeted Therapies

8.2.1 Volasertib (Boehringer Ingelheim)

8.3 Isocitrate Dehydrogenase Inhibitors

8.3.1 ABT-199s (AbbVie, Roche)

8.3.2 FLT3 Inhibitors

8.3.3 Sorafenib (Bayer, Onyx Pharmaceuticals)

8.3.4 Midostaurin (Novartis)

8.3.5 Quizartinib (Daiichi Sankyo)

8.4 Monoclonal Antibodies

8.4.1 SGN-33A (Seattle Genetics)

8.4.2 AMG-330 (Amgen)

8.5 Clinical trials

9. Conclusion

Appendices

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report evaluation form

List of Tables

Table 4.1 Global Acute Myeloid Leukaemia Market by Treatment Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 4.2 Chemotherapy Market by Product Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 4.3 Cytarabine Market Forecasts: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 4.4 Daunorubicin Market Forecasts: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 4.5 Other Chemotherapy Products Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 4.6 Targeted Therapy Market by Product Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 4.7 Midostaurin Market Forecasts: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 4.8 Enasidenib Market Forecast: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 4.9 Other Targeted Therapy Products Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.1 Global Acute Myeloid Leukaemia Market: Revenue ($m), Revenue Share (%) by Region, 2017, 2023, 2028

Table 5.2 Global Acute Myeloid Leukaemia Market by Leading National Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.3 US Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.4 Canada Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.5 Mexico Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.6 Europe Acute myeloid leukaemia Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.7 Germany Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.8 France Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.9 United Kingdom Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.10 Italy Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.11 Spain Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.12 Russia Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.13 Rest for Europe Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.14 Asia-Pacific Acute myeloid leukaemia Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.15 Japan Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.16 China Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.17 Australia Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.18 South Korea Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.19 India Acute myeloid leukaemia Market, Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.20 Rest of Asia-Pacific Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.21 LAMEA Acute myeloid leukaemia Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.22 Brazil Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.23 Saudi Arabia Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.24 Republic of South Africa Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.25 Rest of LAMEA Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 6.1 Daiichi Sankyo: Revenue ($m), R&D ($m), 2015-2017

Table 6.2 Daiichi Sankyo Recent Developments

Table 6.3 Celgene: Revenue ($m), R&D ($m), 2015-2017

Table 6.4 Celgene Recent Developments

Table 6.5 TEVA Operating Segments

Table 6.6 TEVA: Revenue ($m), R&D ($m), 2015-2017

Table 6.7 TEVA Recent Developments

Table 6.8 Eisai Operating Segments

Table 6.9 Eisai Revenue ($m), R&D ($m), 2015-2017

Table 6.10 Novartis Operating Segments

Table 6.11 Novartis: Revenue ($m), R&D ($m), 2015-2017

Table 6.12 Novartis Recent Developments

Table 6.13 GSK Operating Segments

Table 6.14 GSK: Revenue ($m), R&D ($m), 2015-2017

Table 6.15 Sunesis: Revenue ($m), R&D ($m), 2015-2017

Table 6.16 Roche Operating Segments

Table 6.17 Roche: Revenue ($m), R&D ($m), 2015-2017

Table 6.18 Roche Recent Developments

Table 6.19 Bristol-Myers: Revenue ($m), 2015-2017

Table 8.1 AML Drugs in the Pipeline: Agent, MOA, Clinical Trial Code

Table 8.2 Completed Clinical Trials for AML

Table 8.3 List of Recruiting Clinical Trials for AML

Table 9.1: Global Acute Myeloid Leukaemia Market by Treatment Type: Revenue ($m), 2017, 2023, 2028

List of Figures

Figure 3.1 Global Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 3.2 Global Acute Myeloid Leukaemia Market Revenue: Market Shares (%), 2017-2028

Figure 4.1 Chemotherapy Market Forecasts: Revenue ($m), 2017-2028

Figure 4.2 Cytarabine Market Forecasts: Revenue ($m), 2017-2028

Figure 4.3 Daunorubicin Market Forecasts: Revenue ($m), 2017-2028

Figure 4.4 Other Chemotherapy Products Market: Revenue ($m), 2017-2028

Figure 4.5 Targeted Therapy Market Forecasts: Revenue ($m), 2017-2028

Figure 4.6 Midostaurin Market Forecasts: Revenue ($m), 2017-2028

Figure 4.7 Enasidenib Market Forecast: Revenue ($m), 2017-2028

Figure 4.8 Other Targeted Therapy Products Market: Revenue ($m), 2017-2028

Figure 5.1 Global Acute Myeloid Leukaemia Market: Revenue ($m) by Leading Nationals, 2017-2028

Figure 5.2 US Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.3 Canada Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.4 Mexico Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.5 Europe Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.6 Germany Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.7 France Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.8 United Kingdom Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.9 Italy Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.10 Spain Acute myeloid leukaemia Market, Revenue ($m), 2017-2028

Figure 5.11 Russia Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.12 Rest of Europe Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.13 Asia-Pacific Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.14 Japan Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.15 China Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.16 Australia Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.17: South Korea Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.18 India Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.19 Rest of Asia-Pacific Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.20 LAMEA Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.21 Brazil Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.22 Saudi Arabia Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.23 Republic of South Africa Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 5.24 Rest of LAMEA Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028

Figure 9.1: Global Acute Myeloid Leukaemia Market by Treatment Type: Revenue ($m), 2017, 2023, 2028

AbbVie

Agios Pharmaceuticals, Inc.

Ambit Biosciences Corporation

Amgen

Animas Corporation

Astex

B. Braun Melsungen AG

Baxter, Becton, Dickinson and Company (BD)

Bayer

Boehringer Ingelheim

Bristol-Myers Squibb Company (Bristol-Myers)

Celator Pharmaceuticals, Inc.

Celgene

Clavis Pharma ASA (Clavis Pharma)

Cyclacel

Daiichi Pharmaceutical

Daiichi Sankyo

Eisai Co., Ltd. (Eisai)

F. Hoffmann-La Roche Ltd. (Roche)

Fresenius SE & Co. KGaA

GlaxoSmithKline plc (GSK)

GLOBOCAN

Hospira

Medtronic

Moog Inc.

NeoMed

Norsk Hydro

Novartis

Onyx Pharmaceuticals

Sankyo

Seattle Genetics

Smiths Group Plc.,

Sunesis Pharmaceuticals, Inc. (Sunesis)

TEVA Pharmaceutical Industries Limited (TEVA)

List of Organizations Mentioned in the Report

American Cancer Organization

Baylor Scott and White Research Institute

Benaroya Research Institute at Virginia Mason

Beth Israel Deaconess Medical Center

Breslin Cancer Center

Center for Blood Disorders and Stem Cell Transplantation

Charles A. Sammons Cancer Center

Columbia University Medical

Dana Farber Cancer Institute

Duke Cancer Center

European Commission

Fred Hutchinson Cancer Research Center

Health Canada

Herbert Irving Comprehensive Cancer Center

Institute of Hematology & Blood Diseases Hospital,Tianjin

James Graham Brown Cancer Center

Legacy Emanuel Hospital & Health Center

Mary Babb Randolph Cancer Center

Massachusetts general Hospital

Mayo Clinic

MD Anderson Cancer Center

Medical College of Wisconsin Cancer Center

Medizinische Klinik und Poliklinik I

Memorial Sloan Kettering Cancer Center

Michigan State University

Nantes University Hospital

National Cancer Institute

New Jersey Hematology Oncology Associates

Northwestern University

Ochsner Medical Center

Penn State Hershey Cancer Institute-Clinical Trials Office

Perelman Center for Advanced Medicine

Princess Margaret Hospital

St. Francis Cancer Center

St. Joseph Mercy Hospital

St. Vincent's Comprehensive Cancer Center

Swedish Cancer Institute

The Gayle and Tom Benson Cancer Center

The University of Hong Kong

The University of Iowa

The University of Texas MD Anderson Cancer Center

Thomas Jefferson University

U.S. Food and Drug Administration (FDA)

UCLA Medical Center, Division of Hematology/Oncology

University Hospital, Caen

University of Kansas Cancer Center

University of Kansas Medical Center Research Institute

University of Kentucky

University of Louisville

University of Michigan Health System

University of Pennsylvania

University of Texas M.D. Anderson Cancer Center

VA Caribbean Healthcare System

Weill Cornell Medical College

Weill Medical College of Cornell University

West Virginia University

World Health Organization (WHO)

Download sample pages

Complete the form below to download your free sample pages for Global Acute Myeloid Leukaemia Market Forecast 2018-2028

Download sample pages

Complete the form below to download your free sample pages for Global Acute Myeloid Leukaemia Market Forecast 2018-2028

Case studies

Need customized work?

Report overview

Methodology

Client testimonials

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Connect with us

Visiongain Pharma

Latest Pharma news

Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033

The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.

27 September 2023

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033

The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.

25 September 2023

READ

Visiongain Publishes Anti-infective Vaccines Market Report 2023-2033

The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.

21 September 2023

READ

Visiongain Publishes Contract Research Organisations (CROs) Market Report 2023-2033

The global Contract Research Organisations (CROs) market was valued at US$68.9 billion in 2023 and is projected to grow at a CAGR of 10.6% during the forecast period 2023-2033.

14 September 2023

READ

Industries > Pharma > Global Acute Myeloid Leukaemia Market Forecast 2018-2028

Back to Pharma Reports

Global Acute Myeloid Leukaemia Market Forecast 2018-2028

Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib

Download sample pages

Related reports

Pharmaceutical Contract Manufacturing Market 2018-2028

Global Melanoma Drugs Market 2018-2028

Biologics Market Trends and Forecasts 2018-2028

Gene Therapy R&D and Revenue Forecasts 2018-2028

Global Biosimilars and Follow-On Biologics Market 2019-2029

Global Stem Cell Technologies and Applications Market 2018-2028

Top 30 Oncology Drugs Manufacturers 2019

Global Blood Cancer Market Forecast to 2028

Global Biosimilar Monoclonal Antibodies Forecast 2018-2028

Global Liquid Biopsy Market Forecast 2018-2028

Download sample pages

Share

Connect with us

Latest Pharma news

Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033

Visiongain Publishes Anti-infective Vaccines Market Report 2023-2033

Visiongain Publishes Contract Research Organisations (CROs) Market Report 2023-2033

Our Clients